NCT03791424

Brief Summary

It has been described that sympathetic activity, measured as changes in electrical skin resistance (SR), may be used to assess the adequacy of general anaesthesia. Our prospective study investigated how far measurements of skin resistance can help determine level of sedation. The secondary aim was to investigate if changes in skin resistance can be used for assessing recovery from anaesthesia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
28

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Oct 2014

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2014

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 26, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 26, 2015

Completed
3.2 years until next milestone

First Submitted

Initial submission to the registry

September 17, 2018

Completed
4 months until next milestone

First Posted

Study publicly available on registry

January 2, 2019

Completed
Last Updated

January 3, 2019

Status Verified

December 1, 2018

Enrollment Period

9 months

First QC Date

September 17, 2018

Last Update Submit

December 31, 2018

Conditions

Keywords

sedationmidazolamskin resistancemeasurements

Outcome Measures

Primary Outcomes (1)

  • Changes of skin resistence (percent from base-line values measured in ohms) during sedation

    Investigation how far measurements of skin resistance can help determine level of sedation induced by intravenous midazolam

    10 min. before administration and 5 min. after administration of midazolam (total 15 min.)

Secondary Outcomes (1)

  • Changes of skin resistence (percent from base-line values and values before termination of inhalational agent administration measured in ohms) during recovery from anaesthesia

    From termination of inhalational agent administration till recovery to verbal comunication (expected time max. 15 min)

Study Arms (2)

Midazolam

EXPERIMENTAL

Midazolam 2 mg was administered 5 min. after placebo and 5 min. before inducton to general anaesthesia IV.

Drug: Midazolam

Control

PLACEBO COMPARATOR

Normal saline 5 ml was administered 10 min. after insertion of intravenous cannula IV..

Drug: Midazolam

Interventions

Administering premedication with sedative drug to relieve anxiety

Also known as: Sedation
ControlMidazolam

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • adult patients scheduled for knee arthroscopy or minor plastic surgery under general anaesthesia

You may not qualify if:

  • previous history of taking drugs affecting mental functions, history of psychic illness, implanted electrical device, know allergy to benzodiazepines, myasthenia gravis, ASA classification ASA 3 and more. All patients consented not to use any medication for sedation or anxiety, opioid analgesics, ethanol and illicit drugs 24 hours before surgery.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Kralovske Vinohrady

Prague, 100 00, Czechia

Location

MeSH Terms

Interventions

Midazolam

Intervention Hierarchy (Ancestors)

BenzodiazepinesBenzazepinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Jiri Malek, M.D.

    University Hospital Kralovske Vinohrady

    PRINCIPAL INVESTIGATOR
  • Alice Kurzova, M.D.

    University Hospital Kralovske Vinohrady

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Placebo of the same volume and colour as active substance
Purpose
DIAGNOSTIC
Intervention Model
CROSSOVER
Model Details: Multimeter DM 3900 was used for measurements of SR. The device was approved for use in humans by the Department of Medical Biophysics and Informatics of the 3rd Medical Faculty of Charles University. Observer's Assessment of Alertness and Sedation scale was used as a standard tool for measurements of sedation level at the same intervals as measurements of SR. 10 min. rest break was given to participants in order that they adapt to the test situation. The rest value of SR was noticed and next all patients were administered placebo first and after 5 min period midazolam 2 mg i.v. After next 5 minutes patients were administered standard general anaesthesia with propofol, oxygen, nitrous oxide 60 % and isoflurane 1 MAC via laryngeal mask and sufentanil as needed. Changes in skin resistance were measured again immediately after stop of volatile anaesthetics till eye opening and verbal contact.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assoc. Prfo. Jiri Malek, CSc.

Study Record Dates

First Submitted

September 17, 2018

First Posted

January 2, 2019

Study Start

October 1, 2014

Primary Completion

June 26, 2015

Study Completion

June 26, 2015

Last Updated

January 3, 2019

Record last verified: 2018-12

Data Sharing

IPD Sharing
Will not share

Locations